FOLH1 and neoplasm: Recent studies in the advanced CRPCa setting, including those investigating PSMA-targeted radioligand therapy such as [177Lu]Lu-PSMA-617, further illustrate how tumour genomic instability and variable PSMA expression impact radionuclide treatment response and PET imaging readouts [25–27].